Highlights of This Issue 937

SPECIAL FEATURES

CCR 20th Anniversary Commentary

939 CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341
Bevery A. Teicher and Kenneth C. Anderson

942 CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer
Clint T. Allen, Barbara Conley, John B. Sunwoo, and Carter Van Waes

CCR Translations

944 Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better
Roxana S. Dronca and Haidong Dong
See related articles, p. 1115 and p. 1127

947 Moving from Evaluation to Value in Cancer Care
Richard L. Schilsky
See related article, p. 1036

CCR Perspectives in Drug Approval

950 FDA Approval: Siltuximab for the Treatment of Multicentric Castleman Disease
Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeanne F. Zirkelbach, Liang Zhao, Julie Bullock, Nitin Mehrotra, Pedro Del Valle, Haeleh Saber, Christopher Sheth, Brenda Gehrke, Robert Justice, Ann Farrell, and Richard Pazdur

Molecular Pathways

955 Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer
Rebecca A. Prievis, Robert L. Coleman, Adrian L. Harris, and Anil K. Sood

962 Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis
Hae-Yun Jung, Laurent Fattet, and Jing Yang

Reviews

969 Zebrafish: A New Companion for Translational Research in Oncology
Jorge Barriuso, Raghavendra Nagaraju, and Adam Hurlstone

976 Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
Valsamo K. Anagnostou and Julie R. Brahmer

CANCER THERAPY: CLINICAL

985 A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

995 CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gamlich, Maryann Gallagher, Prati Lal, Michael Feldman, Paul Zhang, Christopher Colameco, David Lewis, Melissa Langer, Noah Goodman, Susan Dornmeh, Kerri Gogineni, Mark Rosen, Kevin Fox, and Peter O’Dwyer

1002 Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

1010 Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions
1019 A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James C. Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi-Chia R. Lee, Yong F. Li, Mona El-Gamil, and Steven A. Rosenberg

1028 Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg, David G. McFadden, Edwin L. Palmer, Gilbert H. Daniels, and Lori J. Wirth

1036 Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors
Alberto F. Sobrero, Alessandro Pastorino, Daniel J. Sargent, and Paolo Bruzzi
See related commentary, p. 947

1044 A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
Andrew J. Wagner, Wells A. Messersmith, M. Naveed Shaik, Sherry Li, Xinian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, and Anthony B. El-Khoueiry

1052 Nottingham Clinico-Pathological Response Index (NPR1) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

1063 Longitudinal Noninvasive Imaging of Progesterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy
Szeman Ruby Chan, Amy M. Fowler, Julie A. Allen, Dong Zhou, Carmen S. Dence, Terry L. Sharp, Nicole M. Fettig, Farrokh Dehdashli, and John A. Katzenellenbogen

1071 Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Toni K. Choueiri, David J. Figueredo, André P. Fay, Sabina Signoretti, Yuan Liu, Robert Gagnon, Keith Deen, Christopher Carpenter, Peter Benson, Thai H. Ho, Lini Pandite, Paul de Souza, Thomas Powles, and Robert J. Motzer

1078 Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)
Stephanie M. Cushman, Chen Jiang, Ace I. Hatch, Ivo Shitrev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kourosh Owzar, Herbert I. Hurwitz, and Andrew B. Nixon

1087 Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
Pierre Laurent-Puig, Deniz Pekin, Corinne Normand, Steve K. Kostopoulos, Philippe Nizard, Karla Perez-Toralia, Rachel Rowell, Jeff Olson, Preethi Srinivasan, Delphine Le Corre, Theyor Hor, Zakaria El Harrak, Xinyu Li, Darren R. Link, Olivier Bouché, Jean-François Emile, Bruno Landi, Valérie Boige, J. Brian Hutchison, and Valerie Taly

1098 Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

1106 Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Kristan Meetze, Sylvie Vincent, Steven Tyler, Elizabeth K. Maza, Andrea R. Delpere, Steve Bottega, Donna McIntosh, Richard Nicoletti, William M. Winston, Solly Weiler, Bin Feng, Jero Gyuris, and Zhigang Weng

CANCER THERAPY: PRECLINICAL

1115 The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Sara M. Mangbo, Sissela Broos, Erika Fletcher, Niina Veitonmäki, Christina Furebring, Eva Dahlén, Per Norlén, Malin Lindstedt, Thomas H. Tottman, and Peter Ellmark
See related commentary, p. 944
1127  Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies  
Min Dai, Yuen Yee Yip, Ingegerd Hellstrom, and Karl Erik Hellstrom  
See related commentary, p. 944

1139  Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression  
Min H. Kang, Jing Wang, Monish R. Makena, Joo-Sang Lee, Nancy Paz, Connor P. Hall, Michael M. Song, Ruben I. Calderon, Riza E. Cruz, Ashly Hindle, Winford Ko, Jonathan B. Fitzgerald, Daryl C. Drummond, Timothy J. Triche, and C. Patrick Reynolds

1151  Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects  

1161  Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin  
Sevim Dalva-Aydemir, Richa Baijai, Maylyn Martinez, Kehinde I.A. Adekola, Irawati Kandela, Changrong Wei, Seema Singhali, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, and Mala Shanmugam

1172  Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy  

1183  Integrinβ6-Targeted Immunoliposomes Mediate Tumor-Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma  
Benjia Liang, Muhammad Shahbaz, Yang Wang, Huijie Gao, Ruliang Fang, Zhenghua Niu, Song Liu, Ben Wang, Qi Sun, Wei Bo Niu, Enyu Liu, Bayong Wang, and Jun Niu

BIOLOGY OF HUMAN TUMORS

1196  Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer  
Andrew Feber, Manit Arya, Patricia de Winter, Muhammad Saqib, Raj Nigam, Peter R. Malone, Wei Shen Tan, Simon Rodney, Matthias Lechner, Alex Freeman, Charles Jameson, Asif Muneer, Stephan Beck, and John D. Kelly

1207  A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients  
Kristine Kleivi Sahlberg, Giulia Bottai, Bjorn Naume, Barbara Burwinkel, George A. Calin, Anne-Lise Berresen-Dale, and Libero Santarpia

1215  Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma  
Raphael Maréchal, Jean-Baptiste Bachet, Annabelle Calomme, Pieter Demetter, Jean Robert Delpero, Magali Srvec, Jérôme Cros, Armelle Bardier-Dupas, Francesco Puleo, Geneviève Monges, Pascal Hammel, Christophe Louvet, François Paye, Philippe Bachelier, Yves Patrice Le Tret, Jean-Christophe Vaillant, Alain Savanet, Thierry André, Isabelle Salmon, Jacques Devière, Jean-François Emile, and Jean-Luc Van Laethem

1225  Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer  
Xin Zhang, Xiaoyun Yang, Yanli Zhang, Xinfeng Liu, Guixi Zheng, Yongmei Yang, Lili Wang, Lutao Du, and Chuanxin Wang
ABOUT THE COVER

The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue.